It is therefore of interest that a low concentration of the KATP-channel blocker tolbutamide restores normal glucose regulation of glucagon secretion in metabolically compromised islets (Figure 7D) and improves it in islets from donors with T2D (Figures 7E and 7F). The gene discussed is GCG; the disease is type 2 diabetes mellitus.